Patient education › Prostate cancer and PSA
Prostate cancer and PSA
A prostate cancer diagnosis arrives with a vocabulary nobody teaches you. Here is what the numbers on your reports mean, in the order you are likely to meet them.
Walk in prepared
Most people leave a consultation remembering a fraction of what was said, and think of the question they meant to ask on the drive home.
Dr. Weiner uses WellPrept to help patients gather their records and write down their questions ahead of time. It is free, takes about ten minutes, and you do not need to be his patient to use it. If you are seeing another urologist, or preparing for a second opinion anywhere, it works just as well.
Organize your records and questions before you sit down. Free, and yours to keep whichever doctor you see.
What your PSA does and does not tell you
PSA is a protein made by the prostate, by normal tissue as well as by cancer. It is measured in nanograms per millilitre. It is a useful signal and a poor verdict.
One high number is not a diagnosis
PSA rises for reasons that have nothing to do with cancer: an enlarged prostate, inflammation or infection, recent ejaculation, vigorous cycling, a recent catheter. Guidelines are explicit that a newly elevated PSA should simply be repeated before anyone reaches for a biopsy or a scan, because in a substantial share of people the second test comes back normal. Antibiotics are not a routine answer to a raised PSA in someone with no symptoms.
There is no single normal
The old idea of 4.0 as a universal cutoff has not held up. The same number means different things at different ages, and what tends to matter more than any single value is your PSA compared with others your age, and what it does over time. PSA density, which is your PSA divided by the size of your prostate, puts the number in context, because a large prostate makes more PSA without any cancer being present.
A number measured in your forties predicts a great deal
One of the more striking findings in prostate cancer research is how much a single PSA measured in midlife predicts about the next twenty-five years. Men whose PSA sits in the highest fraction for their age in their late forties account for a disproportionate share of prostate cancer deaths decades later. A low value at that age is genuinely reassuring and can justify testing less often.
When screening usually starts and stops
Current AUA and SUO guidance suggests a baseline PSA between ages 45 and 50 for men at average risk, and starting earlier, between 40 and 45, for men at higher risk. Higher risk there means Black men, men carrying an inherited mutation such as BRCA2, and men with a strong family history. For men in their fifties and sixties who choose to be screened, repeating every two to four years is the usual advice, personalized to your own PSA level, health and preferences.
When to stop is deliberately not a fixed birthday. The guidance leans on life expectancy, and notes that men over 75 with a low PSA can often stop or test far less often. Screening is unlikely to help someone whose life expectancy is under ten years, because prostate cancer usually takes longer than that to cause harm.
This is a decision, not a reflex. Guidelines describe prostate cancer screening as preference-sensitive: it should follow a conversation, not be ordered without your knowing. That cuts both ways. You should not be tested without being told, and you should not be left unaware that testing exists.
Reading your pathology report
Almost every treatment conversation traces back to this one page.
Gleason score and Grade Group
A pathologist looks at how far the cancer's architecture has drifted from normal prostate tissue and assigns a pattern from 3 to 5. Two patterns are reported, the most common first, then the second. Added together they give the Gleason score, which is where the confusing numbers come from.
Because Gleason 6 is the lowest grade that exists in practice, being told you have "6 out of 10" frightens people for no reason. The Grade Group system renumbers the same information from 1 to 5 to fix exactly that.
| Grade Group | Gleason | Usually described as |
|---|---|---|
| 1 | 6 (3+3) | Low grade. Very rarely spreads. Usually watched rather than treated. |
| 2 | 7 (3+4) | Favourable intermediate. Mostly well-behaved pattern with some grade 4. |
| 3 | 7 (4+3) | Unfavourable intermediate. The more aggressive pattern predominates. |
| 4 | 8 | High grade. |
| 5 | 9 or 10 | High grade, most aggressive appearance. |
Grade Group 2 and Grade Group 3 are both "Gleason 7" but behave differently. Which number comes first matters.
How much, and where
Your report lists each biopsy core by location, whether cancer was found, and what percentage of the core it filled. Two positive cores out of fourteen is a different situation from eleven out of fourteen at the same grade. The proportion of cores involved feeds directly into your risk group, so ask for the count.
Patterns worth asking about by name
Cribriform and intraductal carcinoma are specific architectural patterns that carry a worse outlook than grade alone would suggest, and guidelines say they should factor into counselling. They are not always mentioned unless you ask.
Perineural invasion means cancer was seen tracking along a nerve. It is common and on its own is usually not decisive.
ASAP and HGPIN are not cancer. ASAP means the pathologist saw something suspicious but not diagnostic and usually prompts further testing. Isolated HGPIN in a single core generally does not require an immediate repeat biopsy.
A second read is normal
Grading is a judgement made by a human being at a microscope, and experienced genitourinary pathologists disagree with the original read often enough to matter. Asking for your slides to be reviewed at a high-volume centre is routine, not an insult to anyone.
Watching carefully is a treatment decision
Active surveillance means monitoring a low-risk cancer closely and treating only if it changes. It is not "doing nothing," and it is not a lesser option handed to people not worth treating. For low-risk disease it is the preferred approach in current guidelines, precisely because treating every such cancer causes more harm than it prevents. It is also worth discussing for favourable intermediate-risk disease.
What the monitoring involves
Broadly: PSA no more often than every six months, a symptom check and examination every one to two years, an MRI if your original biopsy was done without one, and repeat biopsies at intervals rather than once and never again. The point of the repeat biopsy is not paranoia. The first biopsy samples a small fraction of the prostate and can understate what is there, which is why guidelines are firm that MRI cannot simply replace biopsy on surveillance.
What triggers a change
A single rising PSA is usually repeated first, because transient rises are common. Serial rises, a new finding on examination, or higher grade or noticeably more extensive cancer on a surveillance biopsy are what prompt a conversation about treatment. Your age, other health conditions and preferences are part of that conversation too.
The part people find hardest
The medical case for surveillance is strong. The lived experience is a separate question, and the honest answer is that some people find knowing the cancer is still there difficult in a way that does not show up in survival curves. That is legitimate, and worth saying out loud to your doctor rather than carrying quietly.
Worth asking out loud
None of these are rude. A urologist who does this full time expects every one of them.
About the diagnosis
- What is my Grade Group, and what does that mean for how this behaves?
- How many cores had cancer, and how much of each?
- Is there cribriform or intraductal pattern in my sample?
- What risk group am I in, and what puts me there?
- Do I need imaging to check whether it has spread?
About the decision
- Am I a candidate for active surveillance? If not, specifically why not?
- What would you recommend if this were your father or brother?
- How many of this operation do you do a year?
- What happens if I do nothing for three months while I think?
- Would a genomic test change what you would advise?
About treatment
- What are the realistic odds of being continent at six and twelve months?
- What are the odds of recovering erections, given my age and starting point?
- Would I need hormone therapy, and for how long?
- What is the chance I need a second treatment later?
- Is there a clinical trial I should know about?
About second opinions
- Would you send my slides for a second pathology read?
- Is my MRI worth re-reading at a high-volume centre?
- Who would you send a family member to for the option you are not offering?
- How quickly do I actually need to decide?
Sources and further reading
This page was written for patients and reviewed by Dr. Weiner. It reflects current professional guidelines, which are written for clinicians. The patient-facing versions below are free and often easier to read.
- Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, amended 2026), American Urological Association.
- Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, American Urological Association.
- Active Surveillance Patients International, patient-led education and support.
- Urology Care Foundation, the AUA's patient education arm.
- NCCN Guidelines for Patients, free plain-language versions of the treatment guidelines.
Most prostate cancer is slow. Outside specific high-risk situations, a few weeks spent gathering records and getting a second read does not change the outcome. Ask your own doctor whether that applies to you, because the exceptions are real.
This is general education, not medical advice. It cannot account for your imaging, your pathology, your other health conditions or what matters to you. Take it to your own doctor and work through it together. If anything here conflicts with what your urologist has told you, raise it with them directly rather than assuming either of us is wrong.
Last reviewed September 2026 by Adam B. Weiner, MD.